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All rights reserved.enucleation of the prostate (HoLEP).
METHODS We performed an analysis of patients undergoing HoLEP at our institution who underwent same-
day catheter removal after HoLEP. All HoLEPs were performed with Moses 2.0 Optimized for
BPH. Patients were dismissed from postoperative recovery unit to the clinic for catheter removal
and voiding trial.RESULTS To date, 30 patients have undergone same day catheter removal. Median age is 68.6 years (inter-
quartile range [IQR] 61.8-73.3) and preoperative prostate volume 81 mL (IQR 53-114.8). Median
enucleation time was 39.5 minutes (IQR 30.5-53), morcellation time was 5 minutes (IQR 4-12
minutes), and enucleated specimen weight was 52.5 g (IQR 33-81). Twenty-seven (90%) patients
successfully voided on the same day without requiring catheter replacement. All patients were
catheter free by POD1. For patients who successfully passed their voiding trial, the median time
from the end of the procedure to hospital discharge was 2.6 hours (IQR [2.1-2.9]) and from the
end of the HoLEP to catheter removal was 4.9 hours (IQR [3.5-6.0]).CONCLUSION We present for the first time that same day catheter removal is a feasible option in a select popula-
tion of patients undergoing HoLEP. With more study, this has the potential for transforming the
management of BPH, especially larger glands. UROLOGY 00: 1−5, 2020. © 2020 Elsevier Inc.Holmium laser enucleation of the prostate(HoLEP) is a highly effective, minimally inva-sive surgical procedure for benign prostatic
hyperplasia (BPH). HoLEP is a size independent proce-
dure,1 but has had the strongest impact in the manage-
ment of large (>80 g) prostates2 by preventing the need
for more invasive therapies such as open or robotic simple
prostatectomy. Compared to the “gold standard” transure-
thral resection of prostate (TURP), HoLEP has a lower
hospital stay, transfusion rate, retreatment rate and equiv-
alent if not superior postoperative outcomes.3
Surgical BPH treatments are often associated with inpa-
tient hospital stays. TURP, photovaporization of the pros-
tate (PVP) and HoLEP are all traditionally associatedntific and Lumenis
ientific and Lumenis
ientific and Lumenis.
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ted (with revisions): September 29, 2020with at least overnight hospital stays.3,4 Newer technolo-
gies, such as bipolar TURP and 180W PVP, have allowed
those procedures to be more conducive to same day dis-
charge. In an attempt to reduce morbidity of BPH treat-
ment, new therapies have emerged, such as convective
water thermal therapy and prostatic urethral lift,5 with the
goal of same day procedure discharge, minimal morbidity
and reduced duration of indwelling catheter time.
In light of goals to reduce morbidity of HoLEP, investi-
gators have explored ways for HoLEP to be performed as
an outpatient procedure. Multiple series have demon-
strated HoLEP can be done as outpatient procedure in
selected patient populations.6-11 Since these publications,
improvements in laser technology have resulted in
increased energy delivery to tissue, with a resultant clini-
cal in hemostasis over conventional holmium laser during
HoLEP.12 Furthermore, modifying the procedure by mov-
ing away from less blunt scope dissection (ie, peeling) to
more laser and bubble dissection (noncontact lasering)
has also contributed to less bleeding. We sought to deter-
mine if these technical and technological advancements





After obtaining Institutional Review Board approval, we per-
formed a retrospective review of patients undergoing HoLEP who
underwent same day catheter removal at our institution by 3 sur-
geons from November 2019 to March 2020. Patients were offered
same day catheter removal, as a potential option, being aware our
standard practice was to dismiss patients on the same day of sur-
gery and to remove the catheter as an outpatient on postopera-
tive day 1 (POD1). Patients who were not offered same day
catheter removal were those with prostate volumes >250 mL on
preoperative imaging study (all were required to have imaging to
be considered). Additionally, the patient could not actively be
taking therapeutic doses of anticoagulation. Furthermore, only
the first 2 cases of the day were candidates for same day catheter
removal due to time limitations within the clinic.
Per our standard practice, patients underwent general anes-
thesia with a supraglottic airway to avoid neuromuscular paraly-
sis. Narcotics were limited to induction only and not
administered during the remainder of the case or in the recovery
area. All HoLEPs were performed in standard technique utilizing
high-power laser technology, specifically the 550 mm D/F/L fiber
with Moses 2.0 Optimized for BPH (Lumenis Ltd, Yoknaem,
Israel). Technique for HoLEP and utilizing Moses technology is
standard among the 3 surgeons with either a bi- or trilobar enu-
cleation depending on presence of a median lobe using a bottom
up technique,12 with the exception of laser settings of 2 J and 40
Hz or 2J and 60 Hz being used.
Postoperatively, 3 L of normal saline was run as continuous
bladder irrigation at the maximum rate allowed per the tubing,
and the catheter was clamped to assess for hematuria. The deci-
sion to continue irrigation vs discharge for catheter removal was
made by one of the surgeons on the team. Overall this was a judg-
ment call but essentially there needed to be an absence of clotsFigure 1. Same day cath
2
and the urine needed to flow freely in the catheter tubing. A
maximum of 9 L of catheter irrigation were allowed to be run
before the patient was no longer a candidate for same day cathe-
ter removal. No opioids and no anticholinergics were given after
induction. Patients were typically dismissed from the postopera-
tive care unit (POCU) to the clinic for catheter removal, voiding
trial and postvoid residual check. Voiding trial was performed by
retrofilling the catheter with 300-500 mL of saline or until the
patient felt the subjective urge to urinate. The volume voided,
color of urine and postvoid residual were assessed to ensure there
was no concern for hematuria or possible clot retention. Postvoid
residual of less than half the voided volume was considered ade-
quate for passing. Patients were asked to stay within 30 miles of
our facility on POD0, but were not required to come to clinic on
POD1. All patients were contacted within 7 days of catheter
removal for telephone follow-up. A diagram of our process for
same day catheter removal can be found in Figure 1.
There was no external funding for this study. Data were
obtained and statistically analyzed using JMP Pro 14 (SAS Insti-
tute, Cary, NC). Descriptive statistics were performed of preop-
erative, operative, and postoperative outcomes. Median with
interquartile ranges (IQR) are presented for continuous statistics
and total number with percentage are presented for nominal sta-
tistics.RESULTS
A total of 30 patients were included in our cohort. Median age
was 68.6 years (IQR 61.8-73.3) and BMI was 28.5 (IQR 25.5-
33.2). Median prostate volume was 81 mL (IQR 53-114.8) with
a total range of 37-235 mL. There were 9 patients (30%) who
were in urinary retention requiring a urinary catheterizationeter removal process.
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Table 1. Preoperative patient data
n = 30
Median
or Total IQR or Percent
Age 68.6 61.7-73.3
BMI 28.5 25.5-33.2
Prostate volume 81 53-115
Retention n = 8 27%
Prior therapy n = 4 13%
Antiplatelet/anticoagulation n = 6 20%
Peak urine flow (n = 8) 6.4 mL/s 5.1-8.5
Postvoid residual 82 mL 30-132
AUA symptom score 18 13-29
Quality of life 4 3.5-5.5
ARTICLE IN PRESS(indwelling or intermittent) prior to surgery. Of the 21 patients
who were not in urinary retention, 16 were on medication ther-
apy: 11 (52%) on an alpha-1 antagonist only and 6 (29%) were
on combination alpha-1 antagonist and 5-alpha reductase inhib-
itor. Four (13%) patients had previously undergone a prior pro-
cedure to treat BPH, 2 prostatic urethral lifts, 1 PVP and 1
TURP. There were 6 patients (20%) on anticoagulation preop-
eratively, and 1 patient was on therapeutic anticoagulation at
the time of the procedure. This patient had his catheter inadver-
tently removed in the postanesthesia care unit (PACU) after his
continuous bladder irrigation had been shut off and voided suc-
cessfully, so he was included in the results of the study. No
patients underwent preoperative urodynamic studies, since that
is not our standard practice if the patient shows a compromised
uroflowmetry and is endoscopically obstructed on cystoscopy
even after prior surgical intervention. Table 1 has other preoper-
ative data for our cohort. Of note, subjective and objective void-
ing parameters are provided only for those patients who were
not in urinary retention prior to surgery.
ASA score was I-II in 17 patients (57%) and 28 (93%)
patients underwent anesthesia with a supraglottic airway without
neuromuscular paralysis. Median enucleation time was 39.5
minutes (IQR 30.5-53), morcellation time 5 minutes (IQR 4-
12), and enucleated specimen weight was 52.5 g (33-81).
Median time from the end of the procedure to hospital discharge
was 2.6 hours (IQR [2.1-2.9]).
Same day voiding trial was successful in 27 (90%) of patients,
after catheter removal. Median time from end of the procedure
to catheter removal was 4.9 hours (IQR 3.5-6.0). Of the 3
patients who required catheter replacement, 2 patients failed
voiding trial immediately after catheter removal. The third
patient passed his clinic voiding trial, and after 2 subsequent suc-
cessful voids went to the emergency department in urinary reten-
tion. All 3 had 18-Fr coude catheters placed without need for
cystoscopy or use of guidewire and underwent successful catheter
removal on POD1. None of these patients had undergone a prior
BPH surgical therapy.
There were no known 90-day complications or surgical rein-
terventions. There were 16 patients with available follow-up.
Median time to follow-up was 16 weeks (IQR 13-28.5), and 9
patients had virtual follow-up only due to the Covid-19 pan-
demic. Median AUA (American Urological Association) symp-
tom score was 5 (IQR 2-5), quality of life 1 (IQR 0-2). In 7
patients with in person follow-up, postvoid residual was 16 mL
(IQR 8-37) and PSA was 0.7 ng/dl (IQR 0.36-1). Eight patients
(50%) experienced postoperative dysuria that resolved, with the
longest duration in 1 patient being 4 weeks. Six (37.5%) experi-
enced transient stress urinary incontinence, with 1 patientUROLOGY 00 (00), 2020experiencing mild incontinence at 13 weeks postoperatively. No
patients required medical therapy for BPH or LUTS at time of
follow-up.DISCUSSION
Our cohort highlights that same day catheter removal is
feasible in select patients after HoLEP. We demonstrate
90% success of same day catheter removal, and 100% suc-
cess in removal catheters by POD1. Overall, 3 patients
required catheter replacement after same day catheter
removal, 2 after an immediate failed voiding trial and one
10 hours after catheter removal. Of the patients who
required catheter replacement, there were no obvious dif-
ferences between these groups. All patients were catheter
free by POD1. Patients had a significant improvement in
voiding symptoms without lasting dysuria/incontinence.
Although patients with very large glands (>250 mL on
preoperative imaging) were excluded from this approach,
our cohort’s prostate volume is similar to other outpatient
HoLEP series,6,7,11 with a wide range of 37-235 mL. The
successful application of same day catheter removal for
prostates <250 g is encouraging as HoLEP by nature is size
independent1,2 and would apply to the vast majority of
patients undergoing HoLEP. The rate of passage of void-
ing trial on the same day as surgery is also similar to recent
HoLEP studies,11,12 demonstrating there is no added risk
to patient of catheter reinsertion compared to the stan-
dard approach.
Recently, there has been an effort to reassess periopera-
tive HoLEP care and reduce stays postoperatively. Techni-
cal progress and new laser technology have reduced
morbidity and hospital stay associated with HoLEP.12,13
Multiple studies have demonstrated feasibility of HoLEP
as an outpatient case,7-10 including 2 recent studies.6,11
This series builds off the previous work by removing the
catheter on the same day as the procedure, HoLEP can be
transitioned to a true single day encounter for the patient.
Our cohort did not experience significant dysuria, inconti-
nence, or postoperative complications.
There is limited literature regarding same day catheter
removal with TURP and PVP,14,15 and by removing the
catheter the same day we can offer HoLEP with a single
day encounter as well. Although patients required around
2 additional hours in the facility after postprocedure dis-
charge from the hospital, the practice of same day catheter
removal saved patients many more potential hours of
catheterization and a return trip to the clinic. Our clinic is
attached to our hospital, and patients often had a meal in
between hospital dismissal and their appointment for
clinic voiding trial. The timing of catheter removal is
often dictated by clinic scheduling restraints, and not nec-
essarily reflective of actual time needed.
Same day catheter removal brings several benefits to
patients. The first is the reduction in time of indwelling
catheterization. At our institution, we utilize a 22-Fr 3-
way catheter for continuous bladder irrigation and for
effective hematuria drainage. The size of this catheter,3
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even for men managed with indwelling catheter preopera-
tively, increases discomfort after this procedure. Addition-
ally, less indwelling catheter time should theoretically
decrease rate of postoperative urinary tract infections.
Patients also ambulate less with a catheter in place,16,17
which has the potential to increase the risk for postopera-
tive deep venous thrombosis. Catheter dysfunction is also
a postoperative issue, causing for patient concern and
unintended emergency room visits for clogging and/or
poor drainage. With same day catheter removal, patients
are able to pass small clots per urethra that could other-
wise obstruct a catheter. Anecdotally from postoperative
calls within the first week of surgery, patients whose cathe-
ter removal was performed the same day rarely passed uri-
nary clots beyond POD1. They also did not experience
prolonged dysuria/incontinence or postoperative compli-
cation or reintervention.
In order to facilitate same day catheter removal, we pro-
vide a few suggestions from lessons we have learned to
date. It is important to have an effective plan in place for
patients to undergo a successful voiding trial. At our insti-
tution, PACU/POCU do not have time, ability or experi-
ence to carry out effective voiding trials. We initially
found that patients were not ambulated or retrofilled
before voiding trial, and this was leading to false failures.
These patients then went to clinic and passed. The
PACU/POCU’s inability to perform successful voiding tri-
als led to a change in our protocol for same day catheter
removal in HoLEP patients to undergo catheter removal
in our office, which is in the same physical location as our
operating room. Additionally, we hypothesize neuromus-
cular paralysis required for endotracheal intubation may
have a negative effect on postoperative ability to generate
a detrusor contraction. We opted for all patients to
undergo supraglottic airway without paralysis, but two
patients did undergo intubation without the knowledge of
the operating surgeon. Of these patients, 1 of 2 patients
did not void; however, this sample is not large enough to
draw a conclusion. Likewise, we minimized narcotic and
anticholinergic use in these patients to avoid the cogni-
tive and detrusor effects that these medications can cause.
This is the first study demonstrating same day catheter
removal is possible and successful after HoLEP. Although
it is a single center, there are 3 surgeons included, which
increases generalizability. All surgeons are fellowship-
trained in HoLEP and each perform >100 cases annually.
All cases were done with Moses 2.0 Optimized for BPH,
which is technology that may not be available to all pro-
viders at this time. Limitations of this study include retro-
spective review and low sample size. The patients who
were permitted to undergo same day catheter removal
were limited by gland size, anticoagulation, and medical
fitness for an outpatient procedure. The method outlined
for our same day catheter is also dependent on the OR
and clinic to be in close proximity. Patients could be
safely driven by their accompanying adult to a clinic for
catheter removal if it was not attached to the operating
location; however, we found that having the patient walk4
from the OR to the clinic was the best way to initiate nor-
mal bladder function after the HoLEP procedure. A larger
series or multi-institutional series would provide power to
assess for different factors for failure of the same day void-
ing trials such as prior treatment, mode of anesthesia and
other potential factors. However, despite these limita-
tions, this study is the first to demonstrate the feasibility
and high success rate of same day catheter removal after
HoLEP.CONCLUSION
Same day catheter removal after HoLEP is feasible and
safe in selected patients, making the procedure truly mini-
mally invasive for the patients. Notably, this approach
does not worsen postoperative outcomes. Newer laser
technology likely has a significant impact on the success
in these patients due to reduced rates of hematuria. A pro-
spective trial will be helpful to affirm the safety and suc-
cess of the same day catheter removal outpatient HoLEP
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